Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), and Eosinophil-to-Lymphocyte Ratio (ELR) as Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Agusti A, Vogelmeier C, Faner R. COPD 2020: changes and challenges. Am J Physiol Lung Cell Mol Physiol. 2020;319(5):L879–L883. doi:10.1152/ajplung.00429.2020
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165. doi:10.1111/resp.12780
   PubMed Web of Science ®Google Scholar
• Luo Z, Zhang W, Chen L, Xu N. Prognostic value of neutrophil: lymphocyte and platelet: lymphocyte ratios for 28-day mortality of patients with AECOPD. Int J Gen Med. 2021;14:2839–2848. doi:10.2147/IJGM.S312045
   PubMed Web of Science ®Google Scholar
• Leuzzi G, Galeone C, Taverna F, Suatoni P, Morelli D, Pastorino U. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070. doi:10.1183/16000617.0070-2016
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(3):250–255. doi:10.1164/rccm.200605-713OC
   PubMed Web of Science ®Google Scholar
• Yao C, Liu X, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2285–2290. doi:10.2147/COPD.S141760
   PubMed Web of Science ®Google Scholar
• Kang Y, Zhu X, Lin Z, et al. Compare the diagnostic and prognostic value of MLR, NLR and PLR in CRC patients. Clin Lab. 2021;67:9.
   Web of Science ®Google Scholar
• Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery. BMC Pulm Med. 2022;22(1):104. doi:10.1186/s12890-022-01901-7
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284. doi:10.1038/s41598-019-39150-0
   PubMed Web of Science ®Google Scholar
• Huszno J, Kolosza Z. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients. Oncol Lett. 2019;18(6):6275–6283. doi:10.3892/ol.2019.10966
   PubMed Web of Science ®Google Scholar
• Tiainen S, Rilla K, Hamalainen K, Oikari S, Auvinen P. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Breast Cancer Res Treat. 2021;185(1):63–72. doi:10.1007/s10549-020-05925-7
   PubMed Web of Science ®Google Scholar
• Song S, Li C, Li S, Gao H, Lan X, Xue Y. Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer. Onco Targets Ther. 2017;10:3145–3154. doi:10.2147/ott.S138039
   PubMed Web of Science ®Google Scholar
• Fang L, Yan FH, Liu C, et al. Systemic inflammatory biomarkers, especially fibrinogen to albumin ratio, predict prognosis in patients with pancreatic cancer. Cancer Res Treat. 2021;53(1):131–139. doi:10.4143/crt.2020.330
   PubMed Web of Science ®Google Scholar
• Singh J, Shukla D, Gupta S, Shrivastav BR, Tiwari PK. Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC. Cancer Treat Res Commun. 2021;28:100431. doi:10.1016/j.ctarc.2021.100431
   PubMedGoogle Scholar
• Guo L, Ren H, Pu L, Zhu X, Liu Y, Ma X. The prognostic value of inflammation factors in hepatocellular carcinoma patients with hepatic artery interventional treatments: a retrospective study. Cancer Manag Res. 2020;12:7173–7188. doi:10.2147/CMAR.S257934
   PubMed Web of Science ®Google Scholar
• Fois AG, Paliogiannis P, Scano V, et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules. 2020;25(23):5725. doi:10.3390/molecules25235725
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Z, Lin F, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS. 2017;125(10):863–871. doi:10.1111/apm.12722
   PubMed Web of Science ®Google Scholar
• Bozan N, Alpayci M, Aslan M, et al. Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds. Eur Arch Otorhinolaryngol. 2016;273(11):3663–3672. doi:10.1007/s00405-016-3980-y
   PubMed Web of Science ®Google Scholar
• Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016;30(5):597–601. doi:10.1002/jcla.21908
   PubMed Web of Science ®Google Scholar
• Lang D, Ritzberger L, Rambousek V, et al. First-line pembrolizumab mono- or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes. Cancers (Basel). 2021;13(23):6096. doi:10.3390/cancers13236096
   PubMed Web of Science ®Google Scholar
• Wang K, Zhao Q, Yan T, et al. The prognostic value of multiple systemic inflammatory biomarkers in preoperative patients with non-small cell lung cancer. Front Surg. 2022;9:830642. doi:10.3389/fsurg.2022.830642
   PubMed Web of Science ®Google Scholar
• Lee JW, Jeon S, Mun ST, Lee SM. Prognostic value of fluorine-18 fluorodeoxyglucose uptake of bone marrow on positron emission tomography/computed tomography for prediction of disease progression in cervical cancer. Int J Gynecol Cancer. 2017;27(4):776–783. doi:10.1097/IGC.0000000000000949
   PubMed Web of Science ®Google Scholar
• Ohkuma R, Kubota Y, Horiike A, et al. The prognostic impact of eosinophils and the eosinophil-to-lymphocyte ratio on survival outcomes in stage II resectable pancreatic cancer. Pancreas. 2021;50(2):167–175. doi:10.1097/MPA.0000000000001731
   PubMed Web of Science ®Google Scholar
• Gao J, Chen B, Wu S, Wu F. Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations. BMC Pulm Med. 2020;20(1):50. doi:10.1186/s12890-020-1086-1
   PubMed Web of Science ®Google Scholar
• Lamba TS, Sharara RS, Singh AC, Balaan M. Pathophysiology and classification of respiratory failure. Crit Care Nurs Q. 2016;39(2):85–93. doi:10.1097/CNQ.0000000000000102
   PubMedGoogle Scholar
• Rosner B, Glynn RJ, Lee ML. The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics. 2006;62(1):185–192. doi:10.1111/j.1541-0420.2005.00389.x
   PubMed Web of Science ®Google Scholar
• Zhu KW, Wang GM, Li CY, et al. Pharmacokinetics and bioequivalence of two formulations of rosuvastatin following single‐dose administration in healthy Chinese subjects under fasted and fed conditions. Clin Pharmacol Drug Dev. 2022;11(8):987–996. doi:10.1002/cpdd.1112
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen W. A SAS macro for testing differences among three or more independent groups using Kruskal-Wallis and Nemenyi tests. J Huazhong Univ Sci Technolog Med Sci. 2012;32(1):130–134. doi:10.1007/s11596-012-0023-9
   PubMedGoogle Scholar
• Liao QQ, Ren YF, Zhu KW, et al. Long-term prognostic factors in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a 15-year multicenter retrospective study. Front Immunol. 2022;13:913667. doi:10.3389/fimmu.2022.913667
   PubMed Web of Science ®Google Scholar
• Lu K, Liao QQ, Zhu KW, et al. Efficacy and safety of different doses of rivaroxaban and risk factors for bleeding in elderly patients with venous thromboembolism: a real-world, multicenter, observational, cohort study. Adv Ther. 2024;41(1):391–412. doi:10.1007/s12325-023-02717-5
   PubMed Web of Science ®Google Scholar
• Alshabanat A, Otterstatter MC, Sin DD, et al. Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. Int J Chron Obstruct Pulmon Dis. 2017;12:961–971. doi:10.2147/COPD.S124385
   PubMed Web of Science ®Google Scholar
• Roche N, Rabbat A, Zureik M, Huchon G. Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome. Curr Opin Pulm Med. 2010;16(2):112–117. doi:10.1097/MCP.0b013e328335f039
   PubMed Web of Science ®Google Scholar
• Milan S, Bondalapati P, Megally M, et al. Positive expiratory pressure therapy with and without oscillation and hospital length of stay for acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2553–2561. doi:10.2147/COPD.S213546
   PubMed Web of Science ®Google Scholar
• FWS K, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020;25(3):259–266. doi:10.1111/resp.13660
   PubMed Web of Science ®Google Scholar
• Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP
   PubMed Web of Science ®Google Scholar
• Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3(1):5–19. doi:10.4103/2045-8932.109910
   PubMed Web of Science ®Google Scholar
• Sakao S. Chronic obstructive pulmonary disease and the early stage of cor pulmonale: a perspective in treatment with pulmonary arterial hypertension-approved drugs. Respir Investig. 2019;57(4):325–329. doi:10.1016/j.resinv.2019.03.013
   PubMed Web of Science ®Google Scholar
• Bartziokas K, Papaioannou AI, Loukides S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J. 2014;43(1):43–53. doi:10.1183/09031936.00209212
   PubMed Web of Science ®Google Scholar
• Ogan N, Gunay E, Baha A, Candar T, Akpinar EE. The effect of serum electrolyte disturbances and uric acid level on the mortality of patients with acute exacerbation of chronic obstructive pulmonary disease. Turk Thorac J. 2020;21(5):322–328. doi:10.5152/TurkThoracJ.2019.19034
   PubMed Web of Science ®Google Scholar